Nilotinib, a second-generation tyrosine kinase inhibitor, was designed to overcome
resistance of a wide range of BCR-ABL mutants to imatinib. When used in the first-line …

Imatinib mesylate is currently the standard therapy for chronic myeloid leukemia (CML)
patients. Despite the remarkable results achieved with imatinib, the emergence of resistance …

The development of imatinib has resulted in sustained hematologic and cytogenetic
remissions in all phases of chronic myeloid leukemia (CML). Despite the high efficacy …

Nilotinib is a potent selective inhibitor of the BCR-ABL tyrosine kinase approved for use in
patients with newly diagnosed chronic myeloid leukemia in chronic phase (CML-CP), and in …

Introduction: Chronic myelogenous leukemia (CML) is a progressive and often fatal
hematopoietic neoplasm. The Bcr-Abl tyrosine kinase inhibitor imatinib mesylate …

Chronic myeloid leukemia (CML) is the consequence of a single balanced translocation that
produces the BCR-ABL fusion oncogene which is detectable in over 90% of patients at …

Chronic myelogenous leukemia (CML) is a myeloproliferative disorder arising from a single
genetic mutation that leads to an increase in immature myeloid cells in the bone marrow and …

Nilotinib is a second generation ABL tyrosine kinase inhibitor (TKI) that exerts major anti-
leukemic effects in newly diagnosed patients with chronic myeloid leukemia (CML) as well …

Abstract Abstract 1129 Poster Board I-151 Background Nilotinib is a selective and potent
BCR-ABL inhibitor, developed through structure-based drug design, indicated for the …

Nilotinib is a second-generation tyrosine kinase inhibitor that has been approved for the first-
line treatment of chronic-phase chronic myeloid leukemia, based on the results of a …